ArticleAlzheimer's & dementia (New York, N. Y.)
Clinically meaningful changes in cognitive and functional outcomes in a population-based study of cognitive aging.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial.The journal of prevention of Alzheimer's disease · 2026Trial
- Cerebral "Dirty-Appearing" White Matter in Relation to Cognitive Decline and Dementia Risk in Community-Dwelling Older Adults.Neurology · 2026Article
- Clinically meaningful changes in cognitive and functional outcomes in a population-based study of cognitive aging.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionResearch is limited regarding meaningful change thresholds for individual patients on clinical outcome assessments (COAs) frequently used in clinical trials for Alzheimer's disease and related dementias (ADRD), particularly in population-based studies early in the disease course.
methodsThere were 646 study participants in the population-based Mayo Clinic Study of Aging (MCSA), 54-99 years old (47% females), who developed the clinical syndromes of mild cognitive impairment (MCI) with complete data to establish clinically meaningful within-patient change thresholds in cognitive and functional COAs.
resultsUsing the diagnosis of incident MCI as the anchor, mean (95% confidence interval [CI]) annualized estimates of change were: Clinical Dementia Rating (CDR) scale Sum of Boxes (SB) 0.49 (0.43, 0.55), Mini-Mental State Examination (MMSE) -1.01 (-1.12, -0.91), and Functional Activities Questionnaire (FAQ) score 1.04 (0.82, 1.26). DISCUSSION: This study provides within-patient estimates of clinically meaningful change early in disease progression in a community-based sample. Highlights: We studied incident mild cognitive impairment (MCI) participants from a population-based study.Within-patient change thresholds were estimated for clinical outcome assessments (COAs) used in clinical trials for Alzheimer's disease and related dementia (ADRD).These estimates may be used to plan and evaluate clinical trials involving disease-modifying therapies (DMTs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.